H10.411
|
Chronic giant papillary conjunctivitis, right eye
|
H10.412
|
Chronic giant papillary conjunctivitis, left eye
|
H10.413
|
Chronic giant papillary conjunctivitis, bilateral
|
H10.45
|
Other chronic allergic conjunctivitis
|
H65.04
|
Acute serous otitis media, recurrent, right ear
|
H65.05
|
Acute serous otitis media, recurrent, left ear
|
H65.06
|
Acute serous otitis media, recurrent, bilateral
|
H65.111
|
Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), right ear
|
H65.112
|
Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), left ear
|
H65.113
|
Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), bilateral
|
H65.114
|
Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), recurrent, right ear
|
H65.115
|
Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), recurrent, left ear
|
H65.116
|
Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), recurrent, bilateral
|
H65.194
|
Other acute nonsuppurative otitis media, recurrent, right ear
|
H65.195
|
Other acute nonsuppurative otitis media, recurrent, left ear
|
H65.196
|
Other acute nonsuppurative otitis media, recurrent, bilateral
|
H65.21
|
Chronic serous otitis media, right ear
|
H65.22
|
Chronic serous otitis media, left ear
|
H65.23
|
Chronic serous otitis media, bilateral
|
H65.411
|
Chronic allergic otitis media, right ear
|
H65.412
|
Chronic allergic otitis media, left ear
|
H65.413
|
Chronic allergic otitis media, bilateral
|
H65.491
|
Other chronic nonsuppurative otitis media, right ear
|
H65.492
|
Other chronic nonsuppurative otitis media, left ear
|
H65.493
|
Other chronic nonsuppurative otitis media, bilateral
|
H68.021
|
Chronic Eustachian salpingitis, right ear
|
H68.022
|
Chronic Eustachian salpingitis, left ear
|
H68.023
|
Chronic Eustachian salpingitis, bilateral
|
J30.0
|
Vasomotor rhinitis
|
J30.1
|
Allergic rhinitis due to pollen
|
J30.2
|
Other seasonal allergic rhinitis
|
J30.5
|
Allergic rhinitis due to food
|
J30.81
|
Allergic rhinitis due to animal (cat) (dog) hair and dander
|
J30.89
|
Other allergic rhinitis
|
J31.0
|
Chronic rhinitis
|
J33.1
|
Polypoid sinus degeneration
|
J33.8
|
Other polyp of sinus
|
J34.1
|
Cyst and mucocele of nose and nasal sinus
|
J34.81
|
Nasal mucositis (ulcerative)
|
J35.01
|
Chronic tonsillitis
|
J35.02
|
Chronic adenoiditis
|
J35.03
|
Chronic tonsillitis and adenoiditis
|
J35.1
|
Hypertrophy of tonsils
|
J35.2
|
Hypertrophy of adenoids
|
J35.3
|
Hypertrophy of tonsils with hypertrophy of adenoids
|
J44.1
|
Chronic obstructive pulmonary disease with (acute) exacerbation
|
J44.89
|
Other specified chronic obstructive pulmonary disease
|
J45.20
|
Mild intermittent asthma, uncomplicated
|
J45.21
|
Mild intermittent asthma with (acute) exacerbation
|
J45.22
|
Mild intermittent asthma with status asthmaticus
|
J45.30
|
Mild persistent asthma, uncomplicated
|
J45.31
|
Mild persistent asthma with (acute) exacerbation
|
J45.32
|
Mild persistent asthma with status asthmaticus
|
J45.40
|
Moderate persistent asthma, uncomplicated
|
J45.41
|
Moderate persistent asthma with (acute) exacerbation
|
J45.42
|
Moderate persistent asthma with status asthmaticus
|
J45.50
|
Severe persistent asthma, uncomplicated
|
J45.51
|
Severe persistent asthma with (acute) exacerbation
|
J45.52
|
Severe persistent asthma with status asthmaticus
|
J45.991
|
Cough variant asthma
|
J45.998
|
Other asthma
|
L20.0
|
Besnier's prurigo
|
L20.81
|
Atopic neurodermatitis
|
L20.82
|
Flexural eczema
|
L20.84
|
Intrinsic (allergic) eczema
|
L20.89
|
Other atopic dermatitis
|
L27.0
|
Generalized skin eruption due to drugs and medicaments taken internally
|
L27.1
|
Localized skin eruption due to drugs and medicaments taken internally
|
L27.2
|
Dermatitis due to ingested food
|
L27.8
|
Dermatitis due to other substances taken internally
|
L29.9
|
Pruritus, unspecified
|
L50.0
|
Allergic urticaria
|
L50.1
|
Idiopathic urticaria
|
L50.6
|
Contact urticaria
|
L50.8
|
Other urticaria
|
L50.9
|
Urticaria, unspecified
|
R05.2
|
Subacute cough
|
R05.3
|
Chronic cough
|
R05.8
|
Other specified cough
|
R05.9
|
Cough, unspecified
|
R06.02
|
Shortness of breath
|
R06.2
|
Wheezing
|
R09.81
|
Nasal congestion
|
R21
|
Rash and other nonspecific skin eruption
|
R23.8
|
Other skin changes
|
R23.9
|
Unspecified skin changes
|
R43.0
|
Anosmia
|
R43.1
|
Parosmia
|
R43.2
|
Parageusia
|
R43.8
|
Other disturbances of smell and taste
|
R43.9
|
Unspecified disturbances of smell and taste
|
T36.0X5A
|
Adverse effect of penicillins, initial encounter
|
T36.0X5S
|
Adverse effect of penicillins, sequela
|
T36.1X5A
|
Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter
|
T36.1X5S
|
Adverse effect of cephalosporins and other beta-lactam antibiotics, sequela
|
T36.2X5A
|
Adverse effect of chloramphenicol group, initial encounter
|
T36.2X5S
|
Adverse effect of chloramphenicol group, sequela
|
T36.3X5A
|
Adverse effect of macrolides, initial encounter
|
T36.3X5S
|
Adverse effect of macrolides, sequela
|
T36.4X5A
|
Adverse effect of tetracyclines, initial encounter
|
T36.4X5S
|
Adverse effect of tetracyclines, sequela
|
T36.5X5A
|
Adverse effect of aminoglycosides, initial encounter
|
T36.5X5S
|
Adverse effect of aminoglycosides, sequela
|
T36.6X5A
|
Adverse effect of rifampicins, initial encounter
|
T36.6X5S
|
Adverse effect of rifampicins, sequela
|
T36.7X5A
|
Adverse effect of antifungal antibiotics, systemically used, initial encounter
|
T36.7X5S
|
Adverse effect of antifungal antibiotics, systemically used, sequela
|
T36.8X5A
|
Adverse effect of other systemic antibiotics, initial encounter
|
T36.8X5S
|
Adverse effect of other systemic antibiotics, sequela
|
T37.0X5A
|
Adverse effect of sulfonamides, initial encounter
|
T37.0X5S
|
Adverse effect of sulfonamides, sequela
|
T37.1X5A
|
Adverse effect of antimycobacterial drugs, initial encounter
|
T37.1X5S
|
Adverse effect of antimycobacterial drugs, sequela
|
T37.2X5A
|
Adverse effect of antimalarials and drugs acting on other blood protozoa, initial encounter
|
T37.2X5S
|
Adverse effect of antimalarials and drugs acting on other blood protozoa, sequela
|
T37.3X5A
|
Adverse effect of other antiprotozoal drugs, initial encounter
|
T37.3X5S
|
Adverse effect of other antiprotozoal drugs, sequela
|
T37.4X5A
|
Adverse effect of anthelminthics, initial encounter
|
T37.4X5S
|
Adverse effect of anthelminthics, sequela
|
T37.5X5A
|
Adverse effect of antiviral drugs, initial encounter
|
T37.5X5S
|
Adverse effect of antiviral drugs, sequela
|
T38.0X5A
|
Adverse effect of glucocorticoids and synthetic analogues, initial encounter
|
T38.0X5S
|
Adverse effect of glucocorticoids and synthetic analogues, sequela
|
T38.1X5A
|
Adverse effect of thyroid hormones and substitutes, initial encounter
|
T38.1X5S
|
Adverse effect of thyroid hormones and substitutes, sequela
|
T38.2X5A
|
Adverse effect of antithyroid drugs, initial encounter
|
T38.2X5S
|
Adverse effect of antithyroid drugs, sequela
|
T38.3X5A
|
Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter
|
T38.3X5S
|
Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, sequela
|
T38.4X5A
|
Adverse effect of oral contraceptives, initial encounter
|
T38.4X5S
|
Adverse effect of oral contraceptives, sequela
|
T38.5X5A
|
Adverse effect of other estrogens and progestogens, initial encounter
|
T38.5X5S
|
Adverse effect of other estrogens and progestogens, sequela
|
T38.6X5A
|
Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, initial encounter
|
T38.6X5S
|
Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, sequela
|
T38.7X5A
|
Adverse effect of androgens and anabolic congeners, initial encounter
|
T38.7X5S
|
Adverse effect of androgens and anabolic congeners, sequela
|
T38.815A
|
Adverse effect of anterior pituitary [adenohypophyseal] hormones, initial encounter
|
T38.815S
|
Adverse effect of anterior pituitary [adenohypophyseal] hormones, sequela
|
T38.895A
|
Adverse effect of other hormones and synthetic substitutes, initial encounter
|
T38.895S
|
Adverse effect of other hormones and synthetic substitutes, sequela
|
T38.995A
|
Adverse effect of other hormone antagonists, initial encounter
|
T38.995S
|
Adverse effect of other hormone antagonists, sequela
|
T39.015A
|
Adverse effect of aspirin, initial encounter
|
T39.015S
|
Adverse effect of aspirin, sequela
|
T39.095A
|
Adverse effect of salicylates, initial encounter
|
T39.095S
|
Adverse effect of salicylates, sequela
|
T39.1X5A
|
Adverse effect of 4-Aminophenol derivatives, initial encounter
|
T39.1X5S
|
Adverse effect of 4-Aminophenol derivatives, sequela
|
T39.2X5A
|
Adverse effect of pyrazolone derivatives, initial encounter
|
T39.2X5S
|
Adverse effect of pyrazolone derivatives, sequela
|
T39.315A
|
Adverse effect of propionic acid derivatives, initial encounter
|
T39.315S
|
Adverse effect of propionic acid derivatives, sequela
|
T39.395A
|
Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter
|
T39.395S
|
Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], sequela
|
T39.4X5A
|
Adverse effect of antirheumatics, not elsewhere classified, initial encounter
|
T39.4X5S
|
Adverse effect of antirheumatics, not elsewhere classified, sequela
|
T39.8X5A
|
Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter
|
T39.8X5S
|
Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, sequela
|
T40.0X5A
|
Adverse effect of opium, initial encounter
|
T40.0X5S
|
Adverse effect of opium, sequela
|
T40.2X5A
|
Adverse effect of other opioids, initial encounter
|
T40.2X5S
|
Adverse effect of other opioids, sequela
|
T40.3X5A
|
Adverse effect of methadone, initial encounter
|
T40.3X5S
|
Adverse effect of methadone, sequela
|
T40.415A
|
Adverse effect of fentanyl or fentanyl analogs, initial encounter
|
T40.415S
|
Adverse effect of fentanyl or fentanyl analogs, sequela
|
T40.425A
|
Adverse effect of tramadol, initial encounter
|
T40.425S
|
Adverse effect of tramadol, sequela
|
T40.495A
|
Adverse effect of other synthetic narcotics, initial encounter
|
T40.495S
|
Adverse effect of other synthetic narcotics, sequela
|
T40.5X5A
|
Adverse effect of cocaine, initial encounter
|
T40.5X5S
|
Adverse effect of cocaine, sequela
|
T40.695A
|
Adverse effect of other narcotics, initial encounter
|
T40.695S
|
Adverse effect of other narcotics, sequela
|
T40.995A
|
Adverse effect of other psychodysleptics [hallucinogens], initial encounter
|
T40.995S
|
Adverse effect of other psychodysleptics [hallucinogens], sequela
|
T41.0X5A
|
Adverse effect of inhaled anesthetics, initial encounter
|
T41.0X5S
|
Adverse effect of inhaled anesthetics, sequela
|
T41.1X5A
|
Adverse effect of intravenous anesthetics, initial encounter
|
T41.1X5S
|
Adverse effect of intravenous anesthetics, sequela
|
T41.295A
|
Adverse effect of other general anesthetics, initial encounter
|
T41.295S
|
Adverse effect of other general anesthetics, sequela
|
T41.3X5A
|
Adverse effect of local anesthetics, initial encounter
|
T41.3X5S
|
Adverse effect of local anesthetics, sequela
|
T41.5X5A
|
Adverse effect of therapeutic gases, initial encounter
|
T41.5X5S
|
Adverse effect of therapeutic gases, sequela
|
T42.0X5A
|
Adverse effect of hydantoin derivatives, initial encounter
|
T42.0X5S
|
Adverse effect of hydantoin derivatives, sequela
|
T42.1X5A
|
Adverse effect of iminostilbenes, initial encounter
|
T42.1X5S
|
Adverse effect of iminostilbenes, sequela
|
T42.2X5A
|
Adverse effect of succinimides and oxazolidinediones, initial encounter
|
T42.2X5S
|
Adverse effect of succinimides and oxazolidinediones, sequela
|
T42.3X5A
|
Adverse effect of barbiturates, initial encounter
|
T42.3X5S
|
Adverse effect of barbiturates, sequela
|
T42.4X5A
|
Adverse effect of benzodiazepines, initial encounter
|
T42.4X5S
|
Adverse effect of benzodiazepines, sequela
|
T42.5X5A
|
Adverse effect of mixed antiepileptics, initial encounter
|
T42.5X5S
|
Adverse effect of mixed antiepileptics, sequela
|
T42.6X5A
|
Adverse effect of other antiepileptic and sedative-hypnotic drugs, initial encounter
|
T42.6X5S
|
Adverse effect of other antiepileptic and sedative-hypnotic drugs, sequela
|
T42.8X5A
|
Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, initial encounter
|
T42.8X5S
|
Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, sequela
|
T43.015A
|
Adverse effect of tricyclic antidepressants, initial encounter
|
T43.015S
|
Adverse effect of tricyclic antidepressants, sequela
|
T43.025A
|
Adverse effect of tetracyclic antidepressants, initial encounter
|
T43.025S
|
Adverse effect of tetracyclic antidepressants, sequela
|
T43.1X5A
|
Adverse effect of monoamine-oxidase-inhibitor antidepressants, initial encounter
|
T43.1X5S
|
Adverse effect of monoamine-oxidase-inhibitor antidepressants, sequela
|
T43.215A
|
Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, initial encounter
|
T43.215S
|
Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, sequela
|
T43.225A
|
Adverse effect of selective serotonin reuptake inhibitors, initial encounter
|
T43.225S
|
Adverse effect of selective serotonin reuptake inhibitors, sequela
|
T43.295A
|
Adverse effect of other antidepressants, initial encounter
|
T43.295S
|
Adverse effect of other antidepressants, sequela
|
T43.3X5A
|
Adverse effect of phenothiazine antipsychotics and neuroleptics, initial encounter
|
T43.3X5S
|
Adverse effect of phenothiazine antipsychotics and neuroleptics, sequela
|
T43.4X5A
|
Adverse effect of butyrophenone and thiothixene neuroleptics, initial encounter
|
T43.4X5S
|
Adverse effect of butyrophenone and thiothixene neuroleptics, sequela
|
T43.595A
|
Adverse effect of other antipsychotics and neuroleptics, initial encounter
|
T43.595S
|
Adverse effect of other antipsychotics and neuroleptics, sequela
|
T43.615A
|
Adverse effect of caffeine, initial encounter
|
T43.615S
|
Adverse effect of caffeine, sequela
|
T43.625A
|
Adverse effect of amphetamines, initial encounter
|
T43.625S
|
Adverse effect of amphetamines, sequela
|
T43.635A
|
Adverse effect of methylphenidate, initial encounter
|
T43.635S
|
Adverse effect of methylphenidate, sequela
|
T43.655A
|
Adverse effect of methamphetamines, initial encounter
|
T43.655D
|
Adverse effect of methamphetamines, subsequent encounter
|
T43.655S
|
Adverse effect of methamphetamines, sequela
|
T43.695A
|
Adverse effect of other psychostimulants, initial encounter
|
T43.695S
|
Adverse effect of other psychostimulants, sequela
|
T43.8X5A
|
Adverse effect of other psychotropic drugs, initial encounter
|
T43.8X5S
|
Adverse effect of other psychotropic drugs, sequela
|
T44.0X5A
|
Adverse effect of anticholinesterase agents, initial encounter
|
T44.0X5S
|
Adverse effect of anticholinesterase agents, sequela
|
T44.1X5A
|
Adverse effect of other parasympathomimetics [cholinergics], initial encounter
|
T44.1X5S
|
Adverse effect of other parasympathomimetics [cholinergics], sequela
|
T44.2X5A
|
Adverse effect of ganglionic blocking drugs, initial encounter
|
T44.2X5S
|
Adverse effect of ganglionic blocking drugs, sequela
|
T44.3X5A
|
Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
|
T44.3X5S
|
Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela
|
T44.4X5A
|
Adverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter
|
T44.4X5S
|
Adverse effect of predominantly alpha-adrenoreceptor agonists, sequela
|
T44.5X5A
|
Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter
|
T44.5X5S
|
Adverse effect of predominantly beta-adrenoreceptor agonists, sequela
|
T44.6X5A
|
Adverse effect of alpha-adrenoreceptor antagonists, initial encounter
|
T44.6X5S
|
Adverse effect of alpha-adrenoreceptor antagonists, sequela
|
T44.7X5A
|
Adverse effect of beta-adrenoreceptor antagonists, initial encounter
|
T44.7X5S
|
Adverse effect of beta-adrenoreceptor antagonists, sequela
|
T44.8X5A
|
Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
|
T44.8X5S
|
Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, sequela
|
T44.995A
|
Adverse effect of other drug primarily affecting the autonomic nervous system, initial encounter
|
T44.995S
|
Adverse effect of other drug primarily affecting the autonomic nervous system, sequela
|
T45.0X5A
|
Adverse effect of antiallergic and antiemetic drugs, initial encounter
|
T45.0X5S
|
Adverse effect of antiallergic and antiemetic drugs, sequela
|
T45.1X5A
|
Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter
|
T45.1X5S
|
Adverse effect of antineoplastic and immunosuppressive drugs, sequela
|
T45.2X5A
|
Adverse effect of vitamins, initial encounter
|
T45.2X5S
|
Adverse effect of vitamins, sequela
|
T45.3X5A
|
Adverse effect of enzymes, initial encounter
|
T45.3X5S
|
Adverse effect of enzymes, sequela
|
T45.4X5A
|
Adverse effect of iron and its compounds, initial encounter
|
T45.4X5S
|
Adverse effect of iron and its compounds, sequela
|
T45.515A
|
Adverse effect of anticoagulants, initial encounter
|
T45.515S
|
Adverse effect of anticoagulants, sequela
|
T45.525A
|
Adverse effect of antithrombotic drugs, initial encounter
|
T45.525S
|
Adverse effect of antithrombotic drugs, sequela
|
T45.615A
|
Adverse effect of thrombolytic drugs, initial encounter
|
T45.615S
|
Adverse effect of thrombolytic drugs, sequela
|
T45.625A
|
Adverse effect of hemostatic drug, initial encounter
|
T45.625S
|
Adverse effect of hemostatic drug, sequela
|
T45.695A
|
Adverse effect of other fibrinolysis-affecting drugs, initial encounter
|
T45.695S
|
Adverse effect of other fibrinolysis-affecting drugs, sequela
|
T45.7X5A
|
Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, initial encounter
|
T45.7X5S
|
Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, sequela
|
T45.8X5A
|
Adverse effect of other primarily systemic and hematological agents, initial encounter
|
T45.8X5S
|
Adverse effect of other primarily systemic and hematological agents, sequela
|
T46.0X5A
|
Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter
|
T46.0X5S
|
Adverse effect of cardiac-stimulant glycosides and drugs of similar action, sequela
|
T46.1X5A
|
Adverse effect of calcium-channel blockers, initial encounter
|
T46.1X5S
|
Adverse effect of calcium-channel blockers, sequela
|
T46.2X5A
|
Adverse effect of other antidysrhythmic drugs, initial encounter
|
T46.2X5S
|
Adverse effect of other antidysrhythmic drugs, sequela
|
T46.3X5A
|
Adverse effect of coronary vasodilators, initial encounter
|
T46.3X5S
|
Adverse effect of coronary vasodilators, sequela
|
T46.4X5A
|
Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter
|
T46.4X5S
|
Adverse effect of angiotensin-converting-enzyme inhibitors, sequela
|
T46.5X5A
|
Adverse effect of other antihypertensive drugs, initial encounter
|
T46.5X5S
|
Adverse effect of other antihypertensive drugs, sequela
|
T46.6X5A
|
Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter
|
T46.6X5S
|
Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, sequela
|
T46.7X5A
|
Adverse effect of peripheral vasodilators, initial encounter
|
T46.7X5S
|
Adverse effect of peripheral vasodilators, sequela
|
T46.8X5A
|
Adverse effect of antivaricose drugs, including sclerosing agents, initial encounter
|
T46.8X5S
|
Adverse effect of antivaricose drugs, including sclerosing agents, sequela
|
T46.995A
|
Adverse effect of other agents primarily affecting the cardiovascular system, initial encounter
|
T46.995S
|
Adverse effect of other agents primarily affecting the cardiovascular system, sequela
|
T47.0X5A
|
Adverse effect of histamine H2-receptor blockers, initial encounter
|
T47.0X5S
|
Adverse effect of histamine H2-receptor blockers, sequela
|
T47.1X5A
|
Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter
|
T47.1X5S
|
Adverse effect of other antacids and anti-gastric-secretion drugs, sequela
|
T47.2X5A
|
Adverse effect of stimulant laxatives, initial encounter
|
T47.2X5S
|
Adverse effect of stimulant laxatives, sequela
|
T47.3X5A
|
Adverse effect of saline and osmotic laxatives, initial encounter
|
T47.3X5S
|
Adverse effect of saline and osmotic laxatives, sequela
|
T47.4X5A
|
Adverse effect of other laxatives, initial encounter
|
T47.4X5S
|
Adverse effect of other laxatives, sequela
|
T47.5X5A
|
Adverse effect of digestants, initial encounter
|
T47.5X5S
|
Adverse effect of digestants, sequela
|
T47.6X5A
|
Adverse effect of antidiarrheal drugs, initial encounter
|
T47.6X5S
|
Adverse effect of antidiarrheal drugs, sequela
|
T47.7X5A
|
Adverse effect of emetics, initial encounter
|
T47.7X5S
|
Adverse effect of emetics, sequela
|
T47.8X5A
|
Adverse effect of other agents primarily affecting gastrointestinal system, initial encounter
|
T47.8X5S
|
Adverse effect of other agents primarily affecting gastrointestinal system, sequela
|
T48.0X5A
|
Adverse effect of oxytocic drugs, initial encounter
|
T48.0X5S
|
Adverse effect of oxytocic drugs, sequela
|
T48.1X5A
|
Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter
|
T48.1X5S
|
Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], sequela
|
T48.295A
|
Adverse effect of other drugs acting on muscles, initial encounter
|
T48.295S
|
Adverse effect of other drugs acting on muscles, sequela
|
T48.3X5A
|
Adverse effect of antitussives, initial encounter
|
T48.3X5S
|
Adverse effect of antitussives, sequela
|
T48.4X5A
|
Adverse effect of expectorants, initial encounter
|
T48.4X5S
|
Adverse effect of expectorants, sequela
|
T48.5X5A
|
Adverse effect of other anti-common-cold drugs, initial encounter
|
T48.5X5S
|
Adverse effect of other anti-common-cold drugs, sequela
|
T48.6X5A
|
Adverse effect of antiasthmatics, initial encounter
|
T48.6X5S
|
Adverse effect of antiasthmatics, sequela
|
T48.995A
|
Adverse effect of other agents primarily acting on the respiratory system, initial encounter
|
T48.995S
|
Adverse effect of other agents primarily acting on the respiratory system, sequela
|
T49.0X5A
|
Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, initial encounter
|
T49.0X5S
|
Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, sequela
|
T49.1X5A
|
Adverse effect of antipruritics, initial encounter
|
T49.1X5S
|
Adverse effect of antipruritics, sequela
|
T49.2X5A
|
Adverse effect of local astringents and local detergents, initial encounter
|
T49.2X5S
|
Adverse effect of local astringents and local detergents, sequela
|
T49.3X5A
|
Adverse effect of emollients, demulcents and protectants, initial encounter
|
T49.3X5S
|
Adverse effect of emollients, demulcents and protectants, sequela
|
T49.4X5A
|
Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, initial encounter
|
T49.4X5S
|
Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, sequela
|
T49.5X5A
|
Adverse effect of ophthalmological drugs and preparations, initial encounter
|
T49.5X5S
|
Adverse effect of ophthalmological drugs and preparations, sequela
|
T49.6X5A
|
Adverse effect of otorhinolaryngological drugs and preparations, initial encounter
|
T49.6X5S
|
Adverse effect of otorhinolaryngological drugs and preparations, sequela
|
T49.7X5A
|
Adverse effect of dental drugs, topically applied, initial encounter
|
T49.7X5S
|
Adverse effect of dental drugs, topically applied, sequela
|
T49.8X5A
|
Adverse effect of other topical agents, initial encounter
|
T49.8X5S
|
Adverse effect of other topical agents, sequela
|
T50.0X5A
|
Adverse effect of mineralocorticoids and their antagonists, initial encounter
|
T50.0X5S
|
Adverse effect of mineralocorticoids and their antagonists, sequela
|
T50.1X5A
|
Adverse effect of loop [high-ceiling] diuretics, initial encounter
|
T50.1X5S
|
Adverse effect of loop [high-ceiling] diuretics, sequela
|
T50.2X5A
|
Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter
|
T50.2X5S
|
Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, sequela
|
T50.3X5A
|
Adverse effect of electrolytic, caloric and water-balance agents, initial encounter
|
T50.3X5S
|
Adverse effect of electrolytic, caloric and water-balance agents, sequela
|
T50.4X5A
|
Adverse effect of drugs affecting uric acid metabolism, initial encounter
|
T50.4X5S
|
Adverse effect of drugs affecting uric acid metabolism, sequela
|
T50.5X5A
|
Adverse effect of appetite depressants, initial encounter
|
T50.5X5S
|
Adverse effect of appetite depressants, sequela
|
T50.6X5A
|
Adverse effect of antidotes and chelating agents, initial encounter
|
T50.6X5S
|
Adverse effect of antidotes and chelating agents, sequela
|
T50.7X5A
|
Adverse effect of analeptics and opioid receptor antagonists, initial encounter
|
T50.7X5S
|
Adverse effect of analeptics and opioid receptor antagonists, sequela
|
T50.8X5A
|
Adverse effect of diagnostic agents, initial encounter
|
T50.8X5S
|
Adverse effect of diagnostic agents, sequela
|
T50.A15A
|
Adverse effect of pertussis vaccine, including combinations with a pertussis component, initial encounter
|
T50.A15S
|
Adverse effect of pertussis vaccine, including combinations with a pertussis component, sequela
|
T50.A25A
|
Adverse effect of mixed bacterial vaccines without a pertussis component, initial encounter
|
T50.A25S
|
Adverse effect of mixed bacterial vaccines without a pertussis component, sequela
|
T50.A95A
|
Adverse effect of other bacterial vaccines, initial encounter
|
T50.A95S
|
Adverse effect of other bacterial vaccines, sequela
|
T50.B15A
|
Adverse effect of smallpox vaccines, initial encounter
|
T50.B15S
|
Adverse effect of smallpox vaccines, sequela
|
T50.B95A
|
Adverse effect of other viral vaccines, initial encounter
|
T50.B95S
|
Adverse effect of other viral vaccines, sequela
|
T50.Z15A
|
Adverse effect of immunoglobulin, initial encounter
|
T50.Z15S
|
Adverse effect of immunoglobulin, sequela
|
T50.Z95A
|
Adverse effect of other vaccines and biological substances, initial encounter
|
T50.Z95S
|
Adverse effect of other vaccines and biological substances, sequela
|
T50.915A
|
Adverse effect of multiple unspecified drugs, medicaments and biological substances, initial encounter
|
T50.915D
|
Adverse effect of multiple unspecified drugs, medicaments and biological substances, subsequent encounter
|
T50.915S
|
Adverse effect of multiple unspecified drugs, medicaments and biological substances, sequela
|
T50.995A
|
Adverse effect of other drugs, medicaments and biological substances, initial encounter
|
T50.995S
|
Adverse effect of other drugs, medicaments and biological substances, sequela
|
T78.01XA
|
Anaphylactic reaction due to peanuts, initial encounter
|
T78.01XS
|
Anaphylactic reaction due to peanuts, sequela
|
T78.02XA
|
Anaphylactic reaction due to shellfish (crustaceans), initial encounter
|
T78.02XS
|
Anaphylactic reaction due to shellfish (crustaceans), sequela
|
T78.03XA
|
Anaphylactic reaction due to other fish, initial encounter
|
T78.03XS
|
Anaphylactic reaction due to other fish, sequela
|
T78.04XA
|
Anaphylactic reaction due to fruits and vegetables, initial encounter
|
T78.04XS
|
Anaphylactic reaction due to fruits and vegetables, sequela
|
T78.05XA
|
Anaphylactic reaction due to tree nuts and seeds, initial encounter
|
T78.05XS
|
Anaphylactic reaction due to tree nuts and seeds, sequela
|
T78.06XA
|
Anaphylactic reaction due to food additives, initial encounter
|
T78.06XS
|
Anaphylactic reaction due to food additives, sequela
|
T78.07XA
|
Anaphylactic reaction due to milk and dairy products, initial encounter
|
T78.07XS
|
Anaphylactic reaction due to milk and dairy products, sequela
|
T78.08XA
|
Anaphylactic reaction due to eggs, initial encounter
|
T78.08XS
|
Anaphylactic reaction due to eggs, sequela
|
T78.09XA
|
Anaphylactic reaction due to other food products, initial encounter
|
T78.09XS
|
Anaphylactic reaction due to other food products, sequela
|
T78.1XXA
|
Other adverse food reactions, not elsewhere classified, initial encounter
|
T78.1XXS
|
Other adverse food reactions, not elsewhere classified, sequela
|
T78.3XXA
|
Angioneurotic edema, initial encounter
|
T78.3XXS
|
Angioneurotic edema, sequela
|
T78.41XA
|
Arthus phenomenon, initial encounter
|
T78.41XS
|
Arthus phenomenon, sequela
|
T78.49XA
|
Other allergy, initial encounter
|
T78.49XS
|
Other allergy, sequela
|
T88.2XXA
|
Shock due to anesthesia, initial encounter
|
T88.2XXS
|
Shock due to anesthesia, sequela
|
T88.59XA
|
Other complications of anesthesia, initial encounter
|
T88.59XS
|
Other complications of anesthesia, sequela
|
T88.6XXA
|
Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, initial encounter
|
T88.6XXS
|
Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequela
|